ScienceDaily (June 4, 2010) — An extract of green tea appears to have clinical activity with low toxicity in chronic lymphocytic leukemia (CLL) patients who used it in a phase II clinical trial, say researchers at Mayo Clinic.
The findings were presented June 7 during the annual meeting of the American Society of Clinical Oncology (ASCO). They are the latest in a series of Mayo studies to show promise for use of the chemical epigallocatechin gallate (EGCG) -- the major component of...
Malignant gliomas are the most common subtype of primary brain tumor – and one of the deadliest. Even as doctors make steady progress treating other types of solid tumor cancers, from breast to prostate, the most aggressive form of malignant glioma, called a glioblastoma multiforme or GBM, has steadfastly defied advances in neurosurgery, radiation therapy and various conventional or novel drugs.
A large study focused on documenting the strength and fitness of childhood brain tumor survivors has found that many face health challenges as they age. The study led by St. Jude Children's Research Hospital investigators showed that although most participants were young adults in their 20s, many functioned like people in their 60s, making them less likely to live independently or attend college.
NEW YORK (Reuters Health) - People who are friendly and outgoing and those prone to be nervous and moody have at least one thing in common: their personalities do not seem to be connected to their risk of developing or dying from cancer, a new study finds.
The findings, from two long-running studies of Finnish and Swedish twins, add to evidence refuting the theory that there are certain cancer-prone personalities,...
August 16, 2010 08:30 AM Eastern Daylight Time
Morphotek®, Inc. Announces Initiation of a Phase I Study for MORAb-028, an IgM-Type Monoclonal Antibody, in Patients with Advanced Melanoma
EXTON, Pa.--(BUSINESS WIRE)--Morphotek®, Inc., a subsidiary of Eisai Inc., announced today that the John Wayne Cancer Institute in Santa Monica, California has opened enrollment in a Phase I clinical study with MORAb-028 in patients with advanced melanoma.
